Torres GE, Mendoza SJ, Ortega NB, Pichardo P, Martínez LE

Language: Spanish
References: 12
Page: 129-131
PDF size: 144.01 Kb.

Text Extraction

No abstract.

REFERENCES

1. Arenas R y Torres-Guerrero E, Micología médica ilustrada, 6ªed., México, McGraw Hill Interamericana, 2019, pp. 201-14.

2. López-Martínez R, Méndez-Tovar LJ, Hernández-Hernández Fy Castañón-Olivares R, Micología médica. Procedimientos parael diagnóstico de laboratorio, 2ª ed., México, Trillas, 2006, pp.87-91.

3. Moreno-Coutiño G, Arce-Ramírez M, Medina A, Amarillas-VillalvaA, Salas-Vargas V, Madrigal-Kazem R et al., Coccidioidomicosiscutánea. Comunicación de seis casos mexicanos, Rev ChilInfectol 2015; 32(3):339-43.

4. García-García SC, Salas-Alanís JC, Gómez-Flores M, González-González SE, Vera-Cabrera L y Ocampo-Candiani J, Coccidioidomycosisand the skin: a comprehensive review, An Bras Dermatol2015; 90(5):610-21.

5. Sous R, Levkiavska Y, Sharma R, Jariwal R, Amodio D, JohnsonRH et al., Two cases of miliary and disseminated coccidioidomycosisfollowing glucocorticoid therapy and literature review, JInvest Med High Impact Cas Rep 2022; 10:1-7.

6. Hung CY, Hsu AP, Holland SM y Fierer J, A review of innate andadaptive immunity to coccidioidomycosis, Med Mycol 2019;57:S85-92.

7. Bent C, Weng B y Wu P, Disseminated coccidioidomycosis in animmunocompetent patient, Int J Infect Dis 2021; 107:228-31.

8. Hsu AP, Korzeniowska A, Aguilar CC, Gu J, Karlins E, Oler AJ etal., Immunogenetics associated with severe coccidioidomycosis,jci Insight 2022; 7(22):e159491.

9. Odio CD, Marciano BE, Galgiani JN y Holland SM, Risk factorsfor disseminated coccidioidomycosis, United States, Emerg InfDis 2017; 23(2):308-11.

10. Wang CY, Jerng JS, Ko JC, Lin MF, Hsiao CH, Lee LN et al., Disseminatedcoccidioidomycosis (Letters), Emerg Inf Dis 2005; 11(1):177-9.

11. Johnson RH, Sharma R, Kuran R, Fong I y Heidari A, Coccidioidomycosis:a review, J Investig Med 2021; 69: 316-23.

12. Sharifi S, Sharma R, Heidari A y Johnson RH, Disseminated coccidioidomycosis:cutaneous, soft tissue, osseous, and “shotgunintraparenchymal” brain disease, J Investig Med High ImpactCase Rep 2022; 10:1-4.